Reticulocytes ebaring C4d as biomarkers of disease activity for systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 52, Issue 10, 2005, Pages 3087-3099

  Liu, Chau Ching ^a,b   Manzi, Susan ^a   Kao, Amy H ^a   Navratil, Jeannine S ^a   Ruffing, Margie J ^a   Ahearn, Joseph M ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Lupus Center of Excellence   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C4D; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; PEPTIDE FRAGMENT;

ADULT; ARTICLE; CELL SURFACE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; RETICULOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; AGED; CASE REPORT; CROSS-SECTIONAL STUDY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COMPLEMENT C4B; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; RETICULOCYTES;

EID: 26844559344     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21305     Document Type: Article

References (47)

1. Schur PH, Sandson J. Immunological factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968;278:533-8.
2. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res 2002;4:S279-93.
3. Lloyd W, Schur PH. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore) 1981;60:208-17.
4. Valentijn RM, van Overhagen H, Hazevoet HM, Hermans J, Cats A, Daha MR, et al. The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1985;28: 904-13.
5. Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G, Abramson SB. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 1988;31: 632-41.
6. Sturfelt G, Jonasson L, Sjoholm AG. Sequential studies of complement activation in systemic lupus erythematosus. Scand J Rheumatol 1985;14:184-96.
7. Buyon JP, Tamerius J, Belmont HM, Abramson SB. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus: comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992;35:1028-37.
8. Falk RJ, Agustin MD, Dalmasso P, Kim Y, Lam S, Michael A. Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Engl J Med 1985;312:1594-9.
9. Manzi S, Rairie JE, Carpenter AB, Kelly RH, Jagarlapudi SP, Sereika SM, et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 1996;39:1178-88.
10. Mollnes TE, Haga HJ, Burn JG, Nielsen EW, Sjoholm A, Sturfeldt G, et al. Complement activation in patients with systemic lupus erythematosus without nephritis. Rheumatology (Oxford) 1999;38: 933-40.
11. Abrass CK, Nies KM, Louie JS, Border WA, Glassock RJ. Correlation and predictive accuracy of circulating immune complexes with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1980;23:273-82.
12. Esdaile JM, Joseph L, Abrahamowicz M, Danoff D, Clarke AE. Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? J Rheumatol 1996;23:1891-6.
13. Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail. Arthritis Rheum 1996;39:370-8.
14. Liu CC, Ahearn JM, Manzi S. Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future. Curr Rheumatol Rep 2004;6:85-8.
15. Manzi S, Navratil JS, Ruffing MJ, Liu CC, Danchenko N, Nilson SE, et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum 2004;50:3596-604.
16. Tieley CA, Romans DG, Crookston MC. Localization of Chido and Rodgers determinants to the C4d fragment of human C4. Nature 1978;276:713-5.
17. Atkinson JP, Chan AC, Karp DR, Killion CC, Brown R, Spinella D, et al. Origin of the fourth component of complement related Chido and Rodgers blood group antigens. Complement 1988;5: 65-76.
18. Riley RS, Ben-Ezra JM, Goel R, Tidwell A. Reticulocytes and reticulocyte enumeration. J Clin Lab Anal 2001;15:267-94.
19. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
20. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
21. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32: 1107-18.
22. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
23. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
24. Illei GG, Lipsky PE. Biomarkers in systemic lupus erythematosus. Curr Rheumatol Rep 2004;6:382-90.
25. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability [review]. Arthritis Rheum 2004;50:1709-20.
26. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. II. Markers of disease activity [review]. Arthritis Rheum 2004;50:2048-65.
27. Schiffenbauer J, Hahn B, Weisman MH, Simon LS. Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus. Arthritis Rheum 2004;50:2415-22.
28. Atkinson JP, Chan AC, Karp DR, Killion CC, Brown R, Spinella C, et al. Origin of the fourth component of complement related to Chido and Rodgers blood group antigens. Complement 1988;5: 65-76.
29. O'Neill GJ, Yang Sy, Dupont B. Two HOL-linked loci controlling the fourth component of human complement. Proc Natl Acad Sci USA 1978;75:5165-9.
30. Awdeh ZL, Raum D, Alper CA. Genetic polymorphism of human complement C4 and detection of heterozygotes. Nature 1979;282: 205-8.
31. Yu CY, Belt KT, Giles CM, Campbell RD, Porter RR. Structural basis of the polymorphism of human complement C4A and C4B: gene size, reactivity and antigenicity. EMBO J 1986;5:2873-81.
32. Braun L, Schneider PM, Giles CM, Bertrams J, Rittner C. Null alleles of human complement C4. J Exp Med 1990;171:129-40.
33. Isenman DE, Young JR. The molecular basis for the difference in immune hemolysis activity of the Chido and Rodgers isotypes of human complement C4. J Immunol 1984;132:3019-27.
34. Schifferli JA, Steiger G, Paccaud JP, Sjoholm AG. Differences in the biological properties of the two forms of the fourth component (C4). Clin Exp Immunol 1986;63:473-7.
35. Dodds AW, Ren SD, Willis AC, Law SK. The reaction mechanism of the internal thioester in the human complement component C4. Nature 1996;379:177-9.
36. Christiansen FT, Dawkins RI, Uko G. Complement allotyping in SLE: association with C4A null. Aust N Z J Med 1983;13:483-8.
37. Dunkley H, Gatenby PA, Hawkins B, Naito S, Serjeantson SW. Deficiency of C4A is a genetic determinant of systemic lupus erythematosus in three ethnic groups. J Immunogenet 1987;14: 209-18.
38. Howard PF, Hochberg MC, Bias WB, Arnett FC, McLean RH. Relationship between C4 null genes, HLA-C region antigens, and genetic susceptibility to systemic lupus erythematosus in Caucasians and black Americans. Am J Med 1986;81:187-93.
39. Yang Y, Chung EK, Zhou B, Lhotta K, Hebert LA, Biomingham DJ, et al. The intricate role of complement component C4 in human systemic lupus erythematosus. Curr Dir Autoimmun 2004; 7:99-132.
40. Law SK. The covalent binding of C3 and C4. Ann N Y Acad Sci 1983;421:246-58.
41. Dodds AW, Ran XD, Wills AC, Law SK. The reaction mechanism of the internal thioester in the human complement component C4. Nature 1996;379:177-9.
42. Freedman J, Ho M, Barefoot C. Red blood cell-bound C3d in selected hospital patients. Transfusion 1982;22:515-20.
43. Ross GD, Yount WJ, Walport MJ, Winfield, JB, Parker CJ, Fuller CR, et al. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J Immunol 1985;135:2005-14.
44. Schrieber AD, Frank MM. Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J Clin Invest 1972;51:575-82.
45. Schreiber AD, Frank MM. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J Clin Invest 1972;51:583-9.
46. Atkinson JP, Frank MM. Studies on the in vivo effects of antibody: interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man. J Clin Invest 1974;54:339-48.
47. Nardin A, Lindorfer MA, Taylor RP. How are immune complexes bound to the primate erythrocyte complement receptor transferred to acceptor phagocytic cells? Mol Immunol 1999;36:827-35.